Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Validation of the GerdQ questionnaire for the diagnosis of GERD

A study published ahead of print in the Alimentary Pharmacology & Therapeutics validates the GerdQ questionnaire for the diagnosis of gastro-esophageal reflux disease.

News image

The diagnosis of gastro-esophageal reflux disease (GERD) remains a challenge as both invasive methods and symptom-based strategies have limitations.

The symptom-based management of gastro-esophageal reflux disease in primary care may be further optimised with the use of a questionnaire.

Dr Jonasson and his colleauges assessed the diagnostic validity of the GerdQ questionnaire in patients with symptoms suggestive of gastro-esophageal reflux disease.

Patients with symptoms suggestive of gastro-esophageal reflux disease without alarm features, underwent upper endoscopy, and if normal, pH-metry.

The research team reported that patients were followed for 4 weeks and gastro-esophageal reflux disease was completed blinded to the investigator at both visits.

Reflux esophagitis or pathological acid exposure was used as diagnostic references for gastro-esophageal reflux disease.

GERD had a high positive predictive value of 92%
Alimentary Pharmacology & Therapeutics

The team of doctors assessed the diagnostic accuracy for gastro-esophageal reflux disease on symptom response to proton pump inhibitor.

Among the 169 patients, a gastro-esophageal reflux disease cutoff 9 gave the best balance with regard to sensitivity, 66%, and specificity, for gastro-esophageal reflux disease.

The research team reported that the high prevalence of reflux esophagitis resulted in a high proportion of true positives, but at the same time a high proportion of false-negatives.

Consequently, gastro-esophageal reflux disease had a high positive predictive value, 92%, but a low negative predictive value, 22%, for gastro-esophageal reflux disease.

The team of doctors found that the symptom resolution on proton pump inhibitor therapy had high sensitivity, 76%, but low specificity, 33%, for gastro-esophageal reflux disease.

Dr Jonasson's team concluded,  "GerdQ is a useful complementary tool for the diagnosis of gastro-esophageal reflux disease in primary care."

"The implementation of GerdQ could reduce the need for upper endoscopy, and improve resource utilization."

"Symptom resolution on proton pump inhibitor did not predict gastro-esophageal reflux disease."

Aliment Pharmacol Ther 2013: 37(1): 564-572
07 February 2013

Go to top of page Email this page Email this page to a colleague

 01 March 2015

Advanced search
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Questionnaires for GERD
 26 February 2015 
Herbal products and the liver
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 13 February 2015 
Prevalence of microscopic colitis
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patientsí colonoscopist selection
 11 February 2015 
NAFLD and CVD
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization
 05 February 2015 
GERD, dyspepsia and IBS symptoms
 05 February 2015 
Quality of life in Crohn's after antitumor necrosis factor agents
 05 February 2015 
Thalidomide and refractory Crohn's
 04 February 2015 
Telemedicine in IBD
 04 February 2015 
Infliximab and muscle wasting in Crohn's
 04 February 2015 
Resistance mutations in chronic Hep B
 03 February 2015 
Testosterone in advanced liver disease
 03 February 2015 
Mortality in peptic ulcer bleeding
 03 February 2015 
Colonoscopic remission of ulcerative colitis
 02 February 2015 
Colonoscopy and colon cancer risk in IBD
 02 February 2015 
Sirolimus in Hep C virus infected liver graft recipients
 02 February 2015 
Treatment of C. diff in adults

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us